Literature DB >> 36169871

Neurophysiopathological Aspects of Paclitaxel-induced Peripheral Neuropathy.

Roberto Velasco-González1,2, Ulises Coffeen3.   

Abstract

Chemotherapy is widely used as a primary treatment or adjuvant therapy for cancer. Anti-microtubule agents (such as paclitaxel and docetaxel) are used for treating many types of cancer, either alone or in combination. However, their use has negative consequences that restrict the treatment's ability to continue. The principal negative effect is the so-called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a complex ailment that depends on diversity in the mechanisms of action of the different chemotherapy drugs, which are not fully understood. In this paper, we review several neurophysiological and pathological characteristics, such as morphological changes, changes in ion channels, mitochondria and oxidative stress, cell death, changes in the immune response, and synaptic control, as well as the characteristics of neuropathic pain produced by paclitaxel.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chemotherapy; Neuropathic Pain; Neurotoxicity; Paclitaxel

Year:  2022        PMID: 36169871     DOI: 10.1007/s12640-022-00582-8

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.978


  71 in total

Review 1.  The role of sodium channels in chronic inflammatory and neuropathic pain.

Authors:  Ron Amir; Charles E Argoff; Gary J Bennett; Theodore R Cummins; Marcel E Durieux; Peter Gerner; Michael S Gold; Frank Porreca; Gary R Strichartz
Journal:  J Pain       Date:  2006-05       Impact factor: 5.820

Review 2.  The Role of Voltage-Gated Sodium Channels in Pain Signaling.

Authors:  David L Bennett; Alex J Clark; Jianying Huang; Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

3.  Paclitaxel inhibits mRNA transport in axons.

Authors:  Ilja Bobylev; Abhijeet R Joshi; Mohammed Barham; Christian Ritter; Wolfram F Neiss; Ahmet Höke; Helmar C Lehmann
Journal:  Neurobiol Dis       Date:  2015-07-15       Impact factor: 5.996

4.  Effects of xaliproden, a 5-HT₁A agonist, on mechanical allodynia caused by chemotherapeutic agents in mice.

Authors:  Tsugunobu Andoh; Ayumi Sakamoto; Yasushi Kuraishi
Journal:  Eur J Pharmacol       Date:  2013-09-23       Impact factor: 4.432

5.  Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'.

Authors:  N André; D Braguer; G Brasseur; A Gonçalves; D Lemesle-Meunier; S Guise; M A Jordan; C Briand
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

6.  Terminal arbor degeneration--a novel lesion produced by the antineoplastic agent paclitaxel.

Authors:  Gary J Bennett; Guo K Liu; Wen H Xiao; Hai W Jin; Chiang Siau
Journal:  Eur J Neurosci       Date:  2011-03-13       Impact factor: 3.386

7.  Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Sarah J Benbow; Krystyna M Wozniak; Bridget Kulesh; April Savage; Barbara S Slusher; Bruce A Littlefield; Mary Ann Jordan; Leslie Wilson; Stuart C Feinstein
Journal:  Neurotox Res       Date:  2017-04-08       Impact factor: 3.911

8.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

9.  Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat.

Authors:  Nicole Alessandri-Haber; Olayinka A Dina; Jenny J Yeh; Carlos A Parada; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

10.  Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.

Authors:  Todd Bosanac; Robert O Hughes; Thomas Engber; Rajesh Devraj; Andrew Brearley; Kerstin Danker; Kenneth Young; Jens Kopatz; Melanie Hermann; Antoine Berthemy; Susan Boyce; Jonathan Bentley; Raul Krauss
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.